Regen BioPharma Statistics
Total Valuation
Regen BioPharma has a market cap or net worth of 112,392. The enterprise value is 1.09 million.
| Market Cap | 112,392 |
| Enterprise Value | 1.09M |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Regen BioPharma has 561.96 million shares outstanding. The number of shares has increased by 507.33% in one year.
| Current Share Class | 561.96M |
| Shares Outstanding | 561.96M |
| Shares Change (YoY) | +507.33% |
| Shares Change (QoQ) | +85.67% |
| Owned by Insiders (%) | 8.38% |
| Owned by Institutions (%) | n/a |
| Float | 511.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.48 |
| PB Ratio | -0.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.16 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -252.85% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 16.22% |
| Weighted Average Cost of Capital (WACC) | 15.96% |
| Revenue Per Employee | 236,560 |
| Profits Per Employee | -715,689 |
| Employee Count | 1 |
| Asset Turnover | 1.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.55% in the last 52 weeks. The beta is 0.19, so Regen BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -99.55% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 42.56 |
| Average Volume (20 Days) | 29,218,736 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Regen BioPharma had revenue of 236,560 and -715,689 in losses. Loss per share was -0.01.
| Revenue | 236,560 |
| Gross Profit | 236,560 |
| Operating Income | -869,147 |
| Pretax Income | -715,689 |
| Net Income | -715,689 |
| EBITDA | n/a |
| EBIT | -869,147 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 271 in cash and 959,146 in debt, with a net cash position of -958,875 or -0.00 per share.
| Cash & Cash Equivalents | 271 |
| Total Debt | 959,146 |
| Net Cash | -958,875 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -5.36M |
| Book Value Per Share | -0.02 |
| Working Capital | -5.36M |
Cash Flow
| Operating Cash Flow | -477,157 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 125,665 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -367.41% |
| Pretax Margin | -302.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Regen BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -507.33% |
| Shareholder Yield | -507.33% |
| Earnings Yield | -636.78% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 4, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Nov 4, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Regen BioPharma has an Altman Z-Score of -151.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -151.3 |
| Piotroski F-Score | 2 |